Introduction
In Scotland, one in 1,000 men under 65 die every year, due to ischaemic heart disease (IHD). Twenty percent of the Scottish population aged between 65 and 74 report symptomatic angina which is known to be caused by atherosclerosis in the coronary blood vessels. 6 The renin-angiotensin-aldosterone system (RAAS) plays a fundamental role in the development of atherosclerosis and adverse cardiovascular events including acute angina pectoris. There is increasing data to support the concept that a number of adverse effects of angiotensin II (Ang II) are mediated through its downstream mediator aldosterone. If this is indeed the case, angiotensin-converting enzyme (ACE) inhibition and/or angiotensin receptor blockade (ARB) alone, may be insufficient to block the adverse effects of aldosterone. This 'aldosterone escape' is partly because mediators other than angiotensin stimulate aldosterone release, for instance, potassium. 7 Traditionally, the pathologic effects of the RAAS were assumed to result from vasoconstriction induced by Ang II, and salt and water retention due to aldosterone. However, these hormones also have powerful trophic effects, stimulating increased mass in both the arterial wall and left ventricle. 8 In addition, Ang II and aldosterone predispose to vascular inflammation, thrombosis, oxidative stress, and sudden cardiac death. Therapy directed at RAAS overactivity is potentially helpful in improving the prognosis of most patients with atherosclerosis.
Emerging Role of Angiotensin-Converting Enzyme Inhibitors / Angiotensin Receptor Blockers in Cardiovascular Disease
The major effects of Ang II are summarised in Table 1 . 9 The renin-angiotensin system (RAS) plays a major role in cardiovascular disease and during the past decade extensive research investigated the possible clinical benefit of the use of ACE-inhibitors (ACE-Is) in different clinical conditions. Accordingly, these agents have been recommended for the treatment of heart failure, hypertension, and in the management of myocardial infarction (MI).
Major Clinical Trials Demonstrating the Beneficial Effect of ACE-Is in Heart Failure
Since the first studies by Pfeffer 10 conducted with captopril in rats, ACE-Is are known to prevent or delay dilatation of cardiac chambers secondary to MI and to improve the survival of treated animals.
The Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) 11 and the Studies of Left Ventricular Dysfunction (SOLVD) Study, 12 were based on patients with heart failure and A meta-analysis by Garg and Yusuf 13 based on 32 trials including a total of 7,105 patients with chronic heart failure (CHF), evaluated the effects of ACE-Is on mortality and morbidity in CHF. With a minimum follow-up of 10 weeks (> three months in 54% of patients), ACE-Is versus placebo significantly decreased the all-cause mortality, reduced the combined incidence of death and hospitalisation for CHF, and especially decreased mortality from worsening heart failure. This meta-analysis confirmed the major value of ACE-Is, which improve survival, decrease morbidity, relieve symptoms, and increase exercise capacity in patients with symptomatic CHF or isolated LV dysfunction.
Major Clinical Trials Demonstrating the Benefit of ACE-Is in Coronary Artery Disease (including Myocardial Infarction, Unstable Angina and Stable Angina)
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Activation and migration of macrophages 16 (oral captopril [6.25 to 100 mg daily] versus placebo) ACE-Is have been shown to improve LV ejection fraction and reduce mortality and myocardial re-infarction.
In the Heart Outcomes Prevention Evaluation (HOPE) study 17 ACE-Is significantly reduced the rates of death, MI, and stroke in a broad range of high-risk patients who did not have a low ejection fraction or heart failure.
In the EURopean trial On reduction of cardiac events with perindopril in stable coronary Artery disease (EUROPA) 18 perindopril (8 mg once daily) versus placebo reduced cardiovascular risk in a low-risk population with stable CHD and no apparent heart failure.
In contrast, the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) study 19 (tandolapril [2 mg to 4 mg once day] versus placebo), which was conducted following the favourable results of HOPE 17 and EUROPA, 18 was designed to test whether cardiovascular-related mortality, non-fatal MI or revascularisation are reduced when patients with stable CAD, are treated with an ACE-Is. The results however, indicated that in this case ACE-I therapy did not confer any advantage in terms of the composite secondary endpoint of nonfatal MI, cardiovascular-related death or coronary revascularisation. In conclusion, the PEACE study was negative. It was however, seriously underpowered for several reasons. Rather than including 14,100 patients as planned, only 8,290 were randomised. To maintain reasonable power, the primary endpoint was broadened to include revascularisation, although studies have revealed that ACE-inhibition only modestly reduces rates of revascularisation. Furthermore, revascularisation accounted for the vast majority of endpoints in PEACE. Thus, it is not surprising that the results were negative. 20
Role of Aldosterone and Aldosterone Blockade in Cardiovascular Disease Aldosterone Synthesis
Glucocorticoids (corticosterone in the rat and cortisol in humans) and mineralocorticoids (mainly aldosterone in both species) are synthesised from cholesterol, predominantly in the adrenal cortex. The two forms of the cytochrome P-450 enzyme which catalyse the final step of these synthetic pathways are encoded by two closely related genes CYP11B1 and CYP11B2, respectively 21 but display differences in their enzymatic activity, regulation, and tissue distribution. 22 P-450 11ß-hydroxylase (11ß-OHase) 21 synthesises corticosterone from 11-deoxycorticosterone (DOC) in the zona fasciculata and reticularis and is mainly regulated by adrenocorticotropic hormone (ACTH). P-450 aldosterone (Aldo)-synthase, which catalyses synthesis of aldosterone from DOC, is present only in the zona glomerulosa. Its activity is principally controlled by Ang II and potassium and more weakly by ACTH and sodium. 23, 24 While prolonged administration of ACTH causes a decrease in aldosterone synthesis, it is also a potent stimulator of its synthesis in some acute conditions. 25, 26 The Basic Action of Aldosterone Aldosterone used to be thought of as exclusively a hormone that acted on the kidneys to retain sodium, excrete potassium, and increase systemic blood pressure (BP). Aldosterone binds to a specific cytoplasmic receptor leading to increased expression of genes coding for aldosteroneinduced proteins (AIP). These in turn increase synthesis and activation of Na+ and K+ channels, synthesis of Na+/K+/ATPase, and mitochondrial ATP.
The consequence is increased extra cellular fluid (ECF) volume secondary to increased Na+ reabsorption as well as increased K+ and H+ secretion.
The New Biology of Aldosterone
Since the 1990s, there has been a revolution in our understanding of the physiology and biology of aldosterone. The first novel finding was the discovery of, extra-adrenal sites of aldosterone synthesis, 27 including the brain, vascular tissue, and the myocardium. 28, 29 In heart failure, myocardial tissue synthesises even more aldosterone. The second novel finding was that mineralocorticoid receptors (MR) activated by aldosterone are widespread in the body including the brain, vascular tissue, and the myocardium. This means that aldosterone may act in a paracrine fashion in many tissues -that is, locally synthesised aldosterone may act on local aldosterone receptors to mediate local (mostly adverse) effects. These range from vascular endothelial dysfunction to inflammation to widespread tissue injury and repair. Funder et al. 30 showed that MR can be inappropriately activated not only by aldosterone in the context of an appropriate salt status, but also by glucocorticoids by alteration of NADH status through 11beta hydroxysteroid 2 (HSD2) blockade and the generation of reactive oxygen species. MR selectivity depends on the enzyme, 11beta HSD2, which metabolises glucocorticoids into derivatives with little or no affinity for the MR. The pathophysiological implications of epithelial MR being largely occupied but not activated by glucocorticoids when 11beta HSD2 isoperative, but occupied and activated when the enzyme is blocked/deficient, is profound.
From the evidence in animal studies it has long been recognised that high BP can damage
tissues in the brain, kidneys, and heart, but we now know that Ang II and aldosterone can also damage tissues, independent of their BP effects. In other words, Ang II and aldosterone produce tissue damage in two ways: directly and also by increasing BP. Rocha et al. 4 have shown that selective aldosterone blockade or adrenalectomy markedly reduces tissue damage in salinedrinking, spontaneously hypertensive rats, and at doses of aldosterone blockers that do not alter the BP. The most striking data in this regard are from a recent study in which eplerenone (a selective aldosterone blocker), at a dose that does not affect the systolic BP, reduced brain injury in these animals and prolonged their survival. 4 This tissue damage is not unique to the brain because it also has been shown in renal tissue and, more recently, in the heart.
Aldosterone and Endothelial Dysfunction
Ikeda et al. 31 were the first to show that aldosterone interferes with nitric oxide (NO) production in animals. Farquharson and Struthers 32 showed that spironolactone improves endothelial dysfunction in patients with CHF by increasing endogenous vascular NO. This was shown by the fact that spironolactone doubles the vascular response to NG-monomethyl-L-arginine (L-NMMA). This finding is relevant because vascular NO is believed to exert anti-atherosclerotic effects in some circumstances at least.
In animal models of atherosclerosis Rajagopalan et al. 5 showed a similar result with the specific aldosterone blocker, eplerenone. Eplerenone was shown to decrease NADH/NADPH oxidasedependent free radical production and has potential anti-atherosclerotic effects. The concept of the anti-atherosclerotic effect of aldosterone blockade is further strengthened by the recent studies in apolipoprotein E-deficient (E(0)) mice. Aldosterone administration to E(0) mice was shown to increase macrophage oxidative stress and atherosclerotic lesion development while blocking of the MR and inhibition of tissue ACE and/or the angiotensin receptor-1 reduced aldosterone's deleterious pro-oxidative and proatherogenic effects. 33 Most results have been obtained after chronic aldosterone blockade by spironolactone or eplerenone. In patients with heart failure, spironolactone improved acetylcholine-mediated endothelium-dependent vasodilatation and increased NO bioactivity. 32 Bauersachs et al., 34 showed that the addition of spironolactone to ACE inhibition in rats with heart failure resulted in improvement in endothelial vasomotor dysfunction that can be attributed to the normalisation of NO-mediated relaxation through the beneficial modulation of NO balance and superoxide anion formation.
One of the main mechanisms which is thought to account for aldosterone blockade producing its benefits in RALES and EPHESUS, is that it improves endothelial/vascular function (Struthers 2003 ) (Rocha & Stier 2001 ). 4 We showed this first in moderate CHF patients as above and have now shown the same in asymptomatic, mild CHF patients on all standard therapies (ACE-Is, betablockers, statins, aspirin). 35 A number of animal and human studies have suggested that changes in potassium concentrations may directly improve endothelial function by NO pathway. [36] [37] [38] [39] We have also shown that the beneficial effect of aldosterone blockade is independent of the effect of ENaC function and the associated increase in plasma potassium concentrations. 40 This was a double-blind crossover study in patients with CHF, comparing 5 mg/day amiloride with placebo. Unlike our previous observations with spironolactone, 41, 42 a rise in serum potassium of 0.4 mmol/L induced by amiloride had no effect whatsoever on either the basal or stimulated NO activity, nor did amiloride alter endothelial function, vascular ACE activity, heart rate variability (HRV), or collagen turnover. Farquharson and Struthers 43 have gone on to show that endothelial-derived vasorelaxation is also blunted when normal volunteers are acutely infused with aldosterone at a dose that does not alter BP. Therefore, evidence supports the idea that there is an interaction between aldosterone and NO such that aldosterone reduces NO bioactivity while aldosterone blockade increases NO bioactivity. This suggests that aldosteroneinduced tissue fibrosis may be a repair process after aldosterone has produced tissue injury due to endothelial dysfunction possibly causing tissue microinfarcts.
Effects of Aldosterone on Coronary Arteries
Granier et al. in their study showed that cardiacspecific increase in aldosterone production induces coronary dysfunction in aldosterone synthase (AS)-transgenic mice. 44 They showed that cardiac-specific AS overexpression induces a slight increase in the aldosterone concentration in cardiac tissue but major coronary vascular dysfunction in male mice, without altering cardiac structure and function. One major finding was the marked alteration of coronary vascular responsiveness to acetylcholine and bradykinin observed at 15 weeks. There was no cardiac hypertrophy or cardiac fibrosis, probably related to the modest increase of aldosterone concentration in heart and to the absence of hypertension in this model. This study showed that locally produced aldosterone alters coronary vascular function. It is established that aldosterone has effects on vascular reactivity, but the mechanisms are not well understood. 35, 45 The present model of cardiac-specific hyperaldosteronism had distinct features compared with the well-known model of systemic hyperaldosteronism with added salt. 46, 47 In the latter, the high plasma aldosterone level and elevated sodium chloride result in major damage to cardiac cells and fibrosis. In contrast, as noted above, cardiac fibrosis did not develop in the studied transgenic model, most likely because the increase in the cardiac concentration of aldosterone was less marked and was tissue specific unlike the aldosterone-salt model. 44 Conversely, this mouse model demonstrated a specific effect on coronary vascular function. Therefore, results indicate that coronary arteries may be a target for aldosterone. This finding extends previous observations obtained from the rat aldosterone-salt model, in which fibrinoid necrosis and the presence of inflammatory cells surrounding coronary arteries have been demonstrated. 48 More recently, several laboratories have shown a pericoronary inflammatory phenotype that appears early in the aldosteronesalt-treated rats. [49] [50] [51] [52] It is important to underscore that this work demonstrates a novel deleterious effect of cardiac aldosterone. Moreover, it opens new perspectives by suggesting that at levels below those that induce cardiac fibrosis; locally produced aldosterone may have discrete effects that may facilitate the progression toward coronary disease. In addition aldosterone has been shown to induce coronary dysfunction at levels in the range of those reached in clinical situations, 44 and it may be hypothesised that the beneficial effects of anti-aldosterone treatment in cardiovascular diseases such as CHF may be in part a result of protection against aldosteroneinduced alterations of coronary function.
Vascular Effects of Aldosterone
There are suggestions that aldosterone may act not only on endothelium of blood vessels, but also on the smooth muscle layer, and perhaps even on the perivascular adventitial layer. The evidence for aldosterone acting on the smooth muscle layer comes from Duprez et al., 53 who showed an inverse correlation in heart failure patients between large artery compliance and the prevailing level of aldosterone. The evidence for aldosterone acting on the perivascular adventitia comes from Rocha et al., 54 who showed in animal studies that aldosterone can increase perivascular fibrosis around coronary arteries and that spironolactone reduces it. Thus, aldosterone has harmful effects on all three layers of vascular tissue: the endothelium, the smooth muscle, and the perivascular adventitia. These harmful effects could lead to ischaemia and tissue destruction. In addition, aldosterone is now also believed to adversely affect blood clotting. The combination of aldosterone-induced endothelial dysfunction plus aldosterone-induced increased thrombogenicity could be particularly deleterious, producing ischaemia and tissue infarction. The main effect of aldosterone in this regard is its ability to stimulate plasminogen activator inhibitor-1 (PAI-1), which can adversely influence fibrinolysis. 55 Thus, aldosterone can promote a situation in which the vessel wall and the blood in the lumen are both 'sticky', increasing the likelihood of microthrombosis and tissue microinfarcts, which are then repaired by fibrosis.
Another completely separate vascular effect of aldosterone has come to light. It now appears that aldosterone can increase vascular angiotensin responses. Aldosterone has been shown to enhance the binding to Ang II to its receptors and amplify the Ang II response. 32, 56, 57 
Aldosterone and Myocardial Fibrosis
Another prime adverse effect of aldosterone is its ability to stimulate fibrosis in the myocardium. 46 Brilla et al. 46 showed that aldosterone induces biventricular fibrosis in rats and that myocardial fibrosis could be prevented by spironolactone at a dose too low to alter BP. In many animal models, the vascular injury produced by aldosterone is that of segmental or circumferential fibrinoid necrosis of the media, arterial inflammation, and small foci of ischaemic and necrotic damage in the myocardium. 58 Studying myocardial fibrosis in humans is difficult, but investigators have recently proposed that plasma levels of procollagen type III amino-terminal peptide (PIIINP) may be a useful index of myocardial collagen turnover. 59, 60 Using PIIINP, we showed for the first time that aldosterone blockade reduced PIIINP levels in CHF, implying that myocardial fibrosis was also reduced in man by aldosterone blockade. 41 Zannad et al . 61 found that spironolactone had its main effect in the RALES trial in those patients who had high initial levels of PIIINP, which were reduced by spironolactone. This is strong evidence that aldosterone blockade's beneficial effects on cardiac death are mediated at least to some extent by reducing myocardial collagen. Therefore, it is likely that aldosterone causes patchy myocardial fibrosis, which could lower the threshold for malignant ventricular arrhythmias in CHF. This was the major reason for spironolactone reducing mortality in the RALES trial. What we do not know is how much of this fibrosis is a direct effect of aldosterone and how much is a result of aldosterone-induced vasculopathy causing tissue ischaemia and injury. However, reducing left ventricular fibrosis is not the only beneficial effect of aldosterone blockade on left ventricular abnormalities. It appears that aldosterone blockade also reduces left ventricular hypertrophy and improves left ventricular dilatation/dysfunction. 62 Importantly, these beneficial effects occur in CHF and in hypertension. Therefore, a large part of the beneficial effect of aldosterone blockade could be as a result of its effects on left ventricular hypertrophy, left ventricular dysfunction, and left ventricular fibrosis.
Aldosterone Causes Sympathovagal Imbalance
Corticosterone has been the classical inhibitor of the norepinephrine uptake process, used by pharmacologists since the 1950s, and therefore it became possible that a related steroid (aldosterone) would have the same effect.
C O P Y R I G H T J R A A S L I M I T E D R E P R O D U C T I O N P R O H I B I T E D
This was first shown in an animal experiment where aldosterone blocked norepinephrine uptake in the heart in vivo. 63 It was then shown that spironolactone increased myocardial norepinephrine uptake in patients with CHF, as shown by MIBG scanning. It is tempting to speculate further and suggest that because catecholamines are arrhythmogenic their potentiation by aldosterone within the heart may increase arrhythmias and hasten death. It is worth emphasising that once norepinephrine is taken up into myocardial cells, it is quickly metabolised and inactivated. This local myocardial effect of spironolactone does not alter total circulating norepinephrine. 42 A related harmful effect of aldosterone is that it reduces parasympathetic activity. The evidence for this is threefold. Firstly, in an elegant series of animal studies, Wang et al. 64 showed conclusively that aldosterone directly reduces baroreceptor discharge from the carotid sinus and reduces the heart rate response to changes in BP. Secondly, Yee and Struthers found confirmatory evidence in humans in that aldosterone halved the reflex bradycardic response to pressor stimuli. 65 Thirdly, Yee et al. and Macfadyen et al. in their studies of patients with CHF found that, spironolactone reduced heart rate and increased heart rate variability, which is strong evidence for aldosterone having parasympatholytic effects. 41, 42 A hypothesis regarding sympathovagal imbalance is that vascular NO might be a key regulator of autonomic balance. 66 The observation that L-NMMA produces baroreceptor dysfunction in humans favours this concept. 67 If this is correct, it could turn out that the autonomic effects of aldosterone are also attributable to aldosterone's vascular effects and, in particular, its ability to reduce vascular NO. Not only does aldosterone increase cardiac sympathetic activity, but it also decreases parasympathetic activity. This is particularly relevant because the parasympathetic nervous system is believed to oppose the arrhythmogenic effects of the sympathetic nervous system. Indeed, the recent UK heart trial has shown clearly that autonomic dysfunction, as measured by heart rate variability, is a strong independent predictor of mortality in heart failure. 68
Effect of Aldosterone on Magnesium/ Potassium Loss
Another harmful effect of aldosterone is its ability to promote excretion of magnesium and potassium from the body. The importance of retaining magnesium can be illustrated by the fact that magnesium replacement by the intravenous route or by oral supplementation causes a fall in ventricular arrhythmias in CHF. 69 In addition, potassium supplementation can produce a dramatic reduction in cardiovascular events, even suggesting that atherosclerotic events may be reduced by increasing total body levels of magnesium and potassium. 70 Aldosterone Blockade and Heart Failure
The main clinical demonstration of aldosterone's harmful effects comes from two major prospective trials. In the RALES study, patients with severe CHF (New York Heart Association [NYHF] functional class III-IV) were randomised to receive spironolactone or placebo. 1 The trial was discontinued early because after a mean follow-up of 24 months, the relative risk (RR) of death was 0.70 (95% confidence interval [CI] 0.6 to 0.82; p<0.001) among patients receiving spironolactone -that is, a 30% reduction in risk of death with aldosterone blockade. This reduction in mortality was accounted for by both a significant fall in deaths caused by progression of heart failure (RR 0.64, 95% CI 0.51 to 0.80; p<0.001) and to sudden cardiovascular death (RR 0.71, 95% CI 0.54 to 0.95; p=0.02). The reduction in sudden cardiovascular death seen in RALES could be due to many possible mechanisms, ranging from aldosterone worsening endothelial dysfunction and so increasing acute coronary events, to its having arrhythmogenic effects by promoting myocardial fibrosis and depleting potassium and magnesium. 63 The reduction in progressive heart failure deaths was presumably caused by spironolactone improving left ventricular function. More recently, the EPHESUS trial has evaluated use of the selective aldosterone blocker eplerenone in 6,632 patients with acute MI complicated by left ventricular dysfunction and heart failure. 2 Severity of CHF was less pronounced than in RALES, with left ventricular ejection fraction of 33% compared to 25% in the RALES population. Pharmacotherapy also differed: most notably, 75% of patients received beta-blockers versus approximately only 10% of those in RALES. During a mean follow-up of 16 months, patients randomised to eplerenone had a 15% reduction in mortality compared to patients on placebo, and the risk of hospitalisation for heart failure also fell by 15%. Similar to the RALES study, there was a large fall (21% fall) in sudden cardiac death. This indicates that the myocardial protective effect of aldosterone blockade is detectable even in the presence of optimal treatment and in patients close to the acute phase of MI.
Understanding the Significance of Aldosterone Escape
It is necessary to understand the mechanism of aldosterone escape to realise the significance of aldosterone blockade in CVD.
ACE-I therapy does not reliably suppress aldosterone production, and 'aldosterone escape' occurs in up to 40% of patients with CHF. 7 Many people are surprised at the concept of aldosterone escape because they feel that an ACE-I should keep aldosterone levels suppressed. However, if we examine the physiology of aldosterone that was never likely to happen because aldosterone is controlled not only by Ang II, but also by other substances. One of the most important is potassium, and when Ang II levels fall with an ACE-I, potassium increases. Therefore, when you give an ACE-I or an Ang II antagonist, the fall in Ang II should suppress aldosterone, but that is counterbalanced by the fact that an increase in potassium will stimulate aldosterone, see (Figure 1 ). The increase in potassium produced by ACE-I/ARB is due to the reduced potassium clearance secondary to reduced glomerular filtration rate (GFR). Therefore, on the basis of that very simple physiology, it never was likely that an ACE-I or an Ang II antagonist would suppress aldosterone indefinitely, and, indeed data have shown clearly that it does not. Aldosterone concentrations > 144 pg/ml were reported to occur in up to 40% of patients with symptomatic CHF 71 despite use of an ACE-I. In another study, six weeks of captopril treatment produces only a mean fall of 20% in plasma aldosterone concentrations. In this latter study, the aldosterone values varied greatly between patients, from 56 pmol/l to 1,568 pmol/l, despite captopril treatment.
In the CONSENSUS I trial 11 the reduction in deaths with ACE-Is was very striking, but, after about four months, the mortality curves run parallel suggesting that the ACE-I loses its efficacy with time. This could be called ACE-I 'resistance'. In other words, the effect of the drug to some extent was only in the first few months. Why would ACE-I resistance have occurred? The answer is that if we look at levels of Ang II and aldosterone in heart failure patients who are taking an ACE-I, both were elevated to some extent. The dotted line reflects the normal level ( Figure 2 ). There were some patients with a high level of Ang II (15%), and there are some patients with a high level of aldosterone (32%). Therefore, ACE-I resistance could be due to reactivation of Ang II synthesis, to escape of aldosterone or to both.
Data from the RESOLVD 72 trial also demonstrates the phenomenon of aldosterone escape. This was a heart failure trial in which CHF patients were randomised to either an ARB (candesartan), an ACE-I (enalapril), or a combination. The serum aldosterone concentration after 17-weeks was compared with that after 43 weeks. The aldosterone level was not altered at all when the patients were taking only candesartan or the ACE-Is and, in fact, gradually increases with time. ACE-I and ARB or combinations of both temporarily have an impact on aldosterone levels. One could see that this was relatively brief because, by the end of the trial, at 43 weeks, the aldosterone level had risen above baseline levels again exposing the patient again to the risks of elevated aldosterone.
A study by Sato A et al. 73 demonstrated a high incidence of aldosterone escape in patients with essential hypertension with left ventricular hypertrophy despite the use of ACE-Is. The results also suggest that aldosterone escape may reverse the beneficial effects of an ACE-I on left ventricular hypertrophy and emphasises the role of aldosterone blockade in cardiovascular disease.
There is enough evidence that aldosterone antagonists exert beneficial effects on the key processes that promote cardiac deathendothelial dysfunction, myocardial fibrosis, sympathovagal imbalance, and cation loss. Of these four harmful effects of aldosterone, it is possible that three (endothelial dysfunction, left ventricular fibrosis, and sympathovagal imbalance) are attributable to the vascular adverse effect of aldosterone (Figure 3) .
Is the Effect of Spironolactone Disease Specific? Aldosterone Blockade in Patients with Type 2 Diabetes
However, it cannot be assumed that just because aldosterone blockade improves endothelial function in CHF, it will necessarily do the same in CAD. This is because, we recently found that aldosterone blockade actually worsened endothelial dysfunction when given to normotensive diabetics without CHF. 74 Spironolactone actually worsened HbA 1C in these diabetic patients and this probably overwhelmed any tendency for aldosterone blockade to improve endothelial function which might have occurred if HbA 1C had been unchanged.
Conclusion
In essence, aldosterone blockade seems to produce a variety of different effects. These effects are favourable in heart failure, and also in heart failure patients with diabetes, 1 but they appear to be unfavourable with respect to the prognostic markers of endothelial function and • heart rate variability in Type 2 diabetic patients without heart failure (including those already known to benefit from blockade of the RAS). Interestingly, the beneficial effects seen with Ang II suppression in Losartan Investigation For Endpoints reduction in hypertension (LIFE) and Heart Outcomes Prevention Evaluation (HOPE) were greater in the diabetic subgroups of those studies, but the opposite trend was seen with aldosterone blockade in EPHESUS, which again gives credence to findings of Davies et al. cited above.
It therefore seems likely that the effects of spironolactone are at least in part disease-specific. Aldosterone blockade needs to be studied specifically in each precise patient population, and it is therefore necessary to study the effect of aldosterone blockade specifically in CAD patients without heart failure.
Why should aldosterone blockade benefit CAD patients without heart failure as well as CAD patient with heart failure? From the above review there are three main reasons for believing this. Firstly blocking Ang II and blocking aldosterone produce similar biological effects. It is therefore likely that situations where withdrawing angiotensin has produced benefit may also be benefited further by additional aldosterone blockade. This has certainly been the case in heart failure and may turn out to be the case in cardiovascular patients without heart failure. Angiotensin withdrawal was first shown to benefit patients with heart failure but has since gone on to produce added benefits in a wide range of vascular patients without heart failure e.g. HOPE, 17 LIFE, 75 Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS), 76 and EUROPA. 18 Overall, therefore, it is a reasonable hypothesis, that aldosterone blockade will follow in the footsteps of ACE-Is and the HOPE and EUROPA studies and be found to produce similar benefits in vascular patients without heart failure.
However, the second and stronger reason for believing this arises from the fact that one of the main mechanisms which is thought to account for aldosterone blockade producing its benefits in RALES and EPHESUS, is that it improves endothelial/vascular function. 4 We showed this first in moderate CHF patients and have now shown the same in asymptomatic, mild CHF patients on all standard therapies (ACE-Is, betablockers, statins, aspirin). 35 The third reason for thinking aldosterone blockade might benefit CAD patients is that, it is effective in animal models of atherosclerosis 5 and atherosclerosis (as signified by endothelial dysfunction) is the fundamental problem in CAD patients.
Furthermore, aldosterone blockade may be better tolerated in CAD than in CCF for two reasons. Firstly, the patients with CCF often take furosemide and the RAAS activation produced by furosemide might contribute to the potassium and renal problems seen in CCF. Secondly, CCF patients generally have more renal dysfunction than CAD patients and hence the latter should have fewer potassium-related and renal problems than the former. 
